Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Open-house agreement may be overridden by a later exclusive discount contract via formal procurement, causing automatic...
Strict submission requirements: paper documents in duplicate or qualified electronic signature. Incomplete or late subm...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Supply of Infliximab (ATC L04AB02) under non-exclusive discount agreements
- Open-house model; no selection or award procedure
Show full summary
Open-house model for non-exclusive discount agreements on Infliximab (ATC L04AB02) by AOK Bayern. All qualified pharmaceutical enterprises can join at any time until 05.09.2026. Contracts run from 01.11.2024 to 31.10.2026. No award criteria; eligibility requires only a signed declaration of reliability. No estimated value provided.
Risks
Open-house agreement may be overridden by a later exclusive discount contract via formal procurement, causing automatic...
Strict submission requirements: paper documents in duplicate or qualified electronic signature. Incomplete or late subm...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical enterprise
Administrative
- Submit signed declaration of reliability
- Submit signed contract and annex specifying the pharmaceutical product(s)
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Infliximab, ATC L04AB02
Non-exclusive discount agreements for Infliximab. Open to all pharmaceutical enterprises meeting eligibility. Contracts can be concluded anytime until 05.09.2026, starting on the 1st of the following month if complete documents are received by the 5th of a month.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 16 Sep 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 558403-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Open-house agreement may be overridden by a later exclusive discount contract via formal procurement, causing automatic...
Strict submission requirements: paper documents in duplicate or qualified electronic signature. Incomplete or late subm...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications